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Swallowing dysfunction is one of the most devastating side effects after definitive radiotherapy (RT) or chemoradiation (CHRT) for head and neck cancer (HNC) and has a major impact on health-related quality of life (HRQoL) [1] [2] [3] [4] [5] [6] .
Recently, we reported on the results of a large multicenter prospective cohort study in which we developed multivariable normal tissue complication probability (NTCP) models for swallowing dysfunction [7] . In that study we identified two independent risk factors for grade 2-4 swallowing dysfunction at 6 months after completion of treatment (SWAL M6 ), including the mean dose to the superior pharyngeal constrictor muscle (superior PCM) and the mean dose to the supraglottic larynx, which is in line with the results reported by other investigators [8] [9] [10] [11] . We subsequently showed that swallowing sparing intensity modulated radiotherapy (SW-IMRT) is expected to result in clinically relevant reductions in the risk of swallowing dysfunction in approximately half of the patients. SW-IMRT refers to IMRT with dose constraints for both the parotid glands as well as for the swallowing organs at risk (SWOARs), without compromising the dose to the planning target volumes (PTV) and the parotid glands [12] . However, the clinical validation of SW-IMRT remains to be determined.
Therefore, the purpose of this study was to clinically validate a previously developed multivariable NTCP model for SWAL M6 in a cohort of patients treated with SW-IMRT and to investigate whether SW-IMRT actually resulted in a reduction of the prevalence of SWAL M6 as compared to standard IMRT (parotid gland sparing IMRT).
Methods and materials

Patients
The study population of this prospective cohort study was composed of 186 consecutive patients treated from September 2010 to September 2014 at the Department of Radiation Oncology of two medical centers in The Netherlands: the VU University Medical Center (VUMC), Amsterdam or the University Medical Center Groningen (UMCG), Groningen. All patients were treated with definitive RT for squamous cell HNC originating from the oral cavity, pharynx or larynx, either alone or in combination with concomitant chemotherapy or cetuximab. All patients were subjected to a standard follow-up program that included prospective evaluation of acute and late toxicity, patient-rated symptoms and HRQoL, prior to, during and at regular intervals after treatment (NCT02435576, clinicaltrials.gov) [11, 13] .
Patients who previously underwent surgery, radiotherapy and/ or chemotherapy and those with prior malignancies, and/or distant metastases were excluded. Patients with RTOG grade 2-4 swallowing dysfunction at baseline were also excluded in order to ensure that the observed swallowing dysfunction was induced by radiation treatment itself and not by tumor extension. Furthermore patients with residual disease or recurrence within 6 months were excluded.
Endpoints
The primary endpoint was defined as grade 2-4 swallowing dysfunction according to the RTOG/EORTC Late Radiation Morbidity Scoring Criteria, as assessed 6 months after completion of treatment (SWAL M6 ), which means that patients were not able to eat solid food and were only able to eat semi-solid food, swallow liquids or were dependent on tube feeding.
Treatment
All organs at risk (OARs), including the salivary glands, and the SWOARs were delineated as previously described [14, 15] . Regions of interest, IMRT planning and optimization for SW-IMRT were described previously in detail [12] .
Study design and statistical analysis
The validation of SW-IMRT was performed according to the model-based approach [16] . Model-based validation means that multivariable NTCP models developed in a population with a certain radiation technique (in this case standard IMRT and three-dimensional conformal RT (3D-CRT)) are also valid in an independent subsequent population treated with another radiation technique (in this case SW-IMRT) (external validation). This implies that dose reductions (DDose) obtained with the new technology result in NTCP reductions (DNTCP) as predicted by the multivariable NTCP model and thus that the new technique indeed contributes to less toxicity. For this purpose, the following steps were made:
Step 1 (NTCP standard ): For all patients, a standard IMRT treatment plan was created, using dose constraints for the parotid glands but without dose constraints for the SWOARs. For this plan, the NTCP value for SWAL M6 (NTCP standard ) was calculated using the equation of the prediction model for SWAL M6 as described by Christianen et al. [7] : NTCP = (1 + e ÀS ) À1 , in which S = À6.09 + (mean dose superior PCM ⁄ 0.057) + (mean dose supraglottic larynx ⁄ 0.037).
This plan was then saved and stored.
Step 2 (NTCP SW-IMRT ): This standard IMRT plan was then further optimized into a SW-IMRT plan with similar planning objectives for the parotid glands and target volumes, but with additional constraints for the SWOARs. During the planning procedures, attempts were made to reduce the dose to the SWOARs as much as possible in an iterative process, until the dose to other organs at risk started to rise (parotid glands, oral cavity or spinal cord) and/or the dose levels to the PTV's were compromised. For this plan, the NTCP value for SWAL M6 (NTCP SW-IMRT ) was calculated with the same equation that was used in step 1.
Subsequently, DNTCP SWALM6 was calculated, defined as NTCP standard À NTCP SW-IMRT , and thus corresponding with the predicted NTCP reduction that could be obtained with SW-IMRT as compared to standard IMRT in each individual patient. Patients were divided into 2 groups, including a LOW DNTCP SWALM6 group if DNTCP SWALM6 was 0-5% and a HIGH DNTCP SWALM6 group if DNTCP SWALM6 was more than 5%. This threshold was chosen in advance on an arbitrary basis.
Step 3 (actual treatment): Patients were then actually treated with SW-IMRT and prospectively followed using exactly the same data registration program as used in the previous population treated with 3D-CRT or standard IMRT in which the multivariable model was developed [7] .
Step 4 (external model validation): The external validation of the NTCP model was done by a number of performance measures of the NTCP model in the SW-IMRT cohort to that obtained in the original cohort treated with standard IMRT or 3D-CRT that was used to develop the model [7] . For this purpose, we used Monte-Carlo simulations using repeated random drawings of the outcomes according to the model NTCP to generate the expected distributions of the performance measures, based on the model and the case-mix of the cohort, and calculated single sided p-values (i.e., testing the null-hypothesis that the actual performance was not worse than expected). Overall model performance was described with the explained variance (using the Nagelkerkes R 2 ) and the scaled Brier score. The Brier score is the average squared difference between the predicted probability and the actual outcome. The scaled Brier score is a recalculated Brier score that will give a more robust comparability of the accuracy of the model. A scaled Brier score should be as close to 1 as possible (a perfect model), and is 0 for a non-informative model [17, 18] . For the discrimination ability of the model, we calculated the area under the receiver operating characteristic curve (AUC), and the discrimination slope, defined as the absolute difference between the mean predicted NTCP value for patients with and without the outcome [17, 18] . Finally, a Hosmer-Lemeshow goodness-of-fit test was performed to evaluate the calibration of the model. Model calibration describes to what extent the observed prevalence in a number of equally-sized subgroups corresponds with the expected values based on the average NTCP-value of each subgroup. The model's predictions fit the data at an acceptable level if the Hosmer-Lemeshow goodness-of-fit test statistic is >0.05 [19] . Since in the previous cohort [7] we only assessed model performance using the AUC, we retrospectively performed all the above mentioned model performance measures in the previous cohort as well.
Step 5 (technique validation): To evaluate the ability of SW-IMRT to reduce the prevalence of SWAL M6 , we analyzed if the observed prevalence of SWAL M6 significantly differed from the average predicted NTCP standard , using a non-parametric two-sided test.
Data were analyzed using SPSS Statistics for Windows, version 19 .
Results
The study population of this prospective cohort study was composed of 186 patients with a mean age of 64 years. The majority of patients were males (74%). The pre-treatment characteristics of the patients are listed in Table 1 .
The mean dose in all SWOARs and the contralateral parotid glands was significantly lower with the SW-IMRT plans compared to the standard IMRT plans, whereas the mean dose in the ipsilateral parotid and submandibular glands remained the same (Table 2A) .
The DNTCP SWALM6 varied widely between individual patients, with a mean DNTCP SWALM6 of 4.9% (range 0.01-17.3%). Out of 186 patients, 87 (47%) were classified as having HIGH DNTCP SWALM6 while 99 patients (53%) were classified as having LOW DNTCP SWALM6 (Fig. 1) . The LOW and HIGH DNTCP SWALM6 groups differed significantly with regard to a number of pretreatment variables ( Table 1 ). The patients in the HIGH DNTCP SWALM6 group had higher T-stages, had more primary tumors originating from nasopharynx and oropharynx, and were more often treated with CHRT or conventional RT (Table 1) . Moreover, the doses delivered to some of the SWOARs were significantly higher (Table 2B and C).
In the standard IMRT and 3D-CRT patient cohort used for model development [7] , the overall model performance was good with a scaled Brier of 0.23 (95% CI 0.15-0.31) and an explained variance (R 2 ) of 0.31 (95% CI 0.21-0.41). Discrimination in terms of the AUC was 0.80 (95% CI 0.75-0.86) with a discrimination slope of 0.22 (95% CI 0.18-0.25). The Hosmer-Lemeshow ''goodness of fit" had a p-value of 0.19, indicating a good agreement between expected and observed rates.
Similar results were seen in the validation of the current SW-IMRT patient cohort. The overall model performance had an actual scaled Brier of 0.13 (95% CI 0.03-0.22, with p = 0.36 for a single sided test with respect to the expected distribution based on the model and the case-mix, such that we cannot reject the null-hypothesis that the performance is not worse than expected) and an actual explained variance (R 2 ) of 0.21 (95% CI 0.08-0.33, p = 0.34). The discrimination ability of the model showed an actual AUC of 0.75 (95% CI 0.68-0.82, p = 0.32) and an actual discrimination slope with a value of 0.14 (95% CI 0.10-0.18, p = 0.30). The Hosmer-Lemeshow ''goodness of fit" had a p = 0.74, indicating a good agreement between expected and observed rates. Fig. 2 shows the calibration plots of both cohorts. The mean predicted NTCP SW-IMRT in all 186 patients was 22.6% (95% CI 20.2-24.9%), which was significantly lower than the mean predicted NTCP standard which was 27.5% (95% CI 24.9-29.9%) (p < 0.001). The observed prevalence of SWAL M6 was 22.6%, which corresponded perfectly with the mean predicted NTCP SW-IMRT values (Fig. 3) .
In the LOW DNTCP SWALM6 group, the mean predicted NTCP standard and mean predicted NTCP SW-IMRT was 23.3% (95% CI 19.2-27.6%) and 21.3% (95% CI 17.4-25.4%), respectively (p < 0.001). In the LOW DNTCP SWALM6 the observed prevalence was 20.2% which corresponded with both 95%-confidence intervals of the mean predicted NTCP standard and NTCP SW-MRT (Fig. 3) .
In the HIGH DNTCP SWALM6 group, the mean predicted NTCP standard was 32.2% (95% CI 30.2-34.3%) while the mean predicted NTCP SW-IMRT was significantly lower, i.e. 24.1% (95% CI 22.1-26.3%) (p < 0.001). The observed prevalence of SWAL M6 in the HIGH DNTCP SWALM6 was 25.3% and was within the mean predicted NTCP SW-IMRT 95%-confidence interval (Fig. 3) .
Discussion
This study is the first to report the clinical validation of SW-IMRT using a model-based approach. Our results show that by adding dose constraints for SWOARs during treatment planning optimization a clinically relevant DNTCP can be obtained in approximately 50% of the patients and that subsequent lower prevalences of SWAL M6 are observed if the dose to the superior PCM and the supraglottic larynx can indeed be sufficiently decreased. In this regard, it should be noted that we arbitrarily defined a DNTCP-threshold of 5% as clinically relevant.
In the current study population, we were able to significantly reduce the dose to the superior PCM and supraglottic larynx resulting in a significant average NTCP reduction from 27.5% obtained with standard IMRT to 22.6% as obtained with SW-IMRT. The expected average NTCP SW-IMRT corresponded perfectly with the observed prevalence of 22.6%. These results are in line with those Oropharynx  64  35  27  27  37  43  Oral cavity  8  4  5  5  3  3  Hypopharynx  21  11  16  16  5  6  Nasopharynx  8  4  1  1  7  8   Treatment modalities  Conventional radiotherapy  51  27  24  24  27  31  .006  Accelerated radiotherapy  63  34  42  43  21  24  Chemoradiation  61  33  24  24  37  43  Bioradiation  11  6  9  9 2 2 * P-value LOW NTCP reduction versus HIGH NTCP reduction, based on chi-square. reported by Feng et al. who observed low rates of dysphagia at 1 year after chemoradiation after IMRT with sparing of the pharyngeal constrictors and glottic regions [20, 21] .
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It should be noted that in this study, we only included patients with primary tumors originating from the oral cavity, nasopharynx, oropharynx, hypopharynx and larynx, while in our previous cohort [7] also other primary tumor sites were included. When confining the analysis to similar tumor sites as used in the current study, the prevalence of SWAL M6 in patients treated with standard IMRT in our previous study was 27.9%, which corresponded nicely with the mean predicted NTCP standard found in the current study (27.5%), indicating that the expected prevalence of SWAL M6 would have been similar to that observed in the previous cohort when treated with standard IMRT.
The NTCP for SWAL M6 with standard IMRT and the DNTCP SWALM6 varied widely between individual patients. We found differences between the pretreatment variables of the patients in the LOW (0-5%) and HIGH (>5%) DNTCP SWALM6 groups. The HIGH DNTCP SWALM6 group, consisted of patients with more advanced T-stages, and with more nasopharyngeal and oropharyngeal cancers, which corresponds with the higher doses administered to the most important SWOARs, i.e. the superior PCM and supraglottic larynx. Consequently, patients in the HIGH DNTCP SWALM6 group more often received CHRT or conventional RT.
As shown in a previous report on the implementation of SW-IMRT [22] , DNTCP obtained with SW-IMRT depend on universus bilateral neck RT, tumor location and the amount of overlap SWOAR-PTV. Also in the current study, we experienced several reasons why DNTCP SWALM6 remained low in some of the patients. In the first place, the SWOARs sometimes partly or even completely overlapped with the PTV, and therefore little to no reduction in the SWOARs could be obtained without compromising the dose to the PTV. Secondly, lowering the dose to the SWOARs in some cases led to an increase in the dose to other OARs which was not allowed according to predefined criteria. Finally, for a small subgroup of patients the initial NTCP was already low and could not be reduced any further.
Recently, Vainshtein et al. reported on favorable long-term patient-reported outcome of swallowing complaints among HPV-positive oropharyngeal cancer patients treated with chemoradiation with IMRT with dose constraints for both salivary glands and a number of swallowing structures, which further support the validity of IMRT aimed at the reduction of dysphagia [23] . The relationship between dose-volume parameters and swallowing dysfunction after RT or CHRT, and on the potential benefit of sparing SWOARs with IMRT, but the clinical relevance of these reductions remained to be determined [2, [21] [22] [23] [24] [25] [26] . Some of the other investigators who previously reported on the potential dosimetric benefits of SW-IMRT, accepted reduced coverage of the (elective) PTV (i.e. by using split field IMRT) [22, 26, [27] [28] [29] [30] , which makes it difficult to compare these results with those from the current study.
In the current study we used the previously described modelbased approach to validate SW-IMRT. The model-based approach is a stepwise methodology, that has been developed to effectively select patients that are expected to benefit most from new radiation delivery techniques aiming at the reduction of radiationinduced side effects, such as proton therapy [16] . However, this method is also applicable for the development and validation of other radiation delivery techniques, such as SW-IMRT.
At present, randomized trials are still considered gold standard in evidence-based medicine. This is certainly true for new interventions aiming at improving treatment efficacy in terms of local control and survival. However, evidence based medicine is not restricted to randomized trials and meta-analyses. It involves tracking down the best external evidence with which to answer our clinical questions [31] . For new radiation techniques that are only aiming at reducing side effects without changing the strategy with regard to tumor control (i.e. target volumes and fractionation), the model-based approach can be considered as a good alternative for an RCT. reported in our previously published papers [7, 12] . In the current paper we reported on phase b. The multivariable NTCP model for SWAL M6 showed a significant relationship between the dose to the superior PCM and supraglottic larynx and SWAL M6 . However, such relationship does not strictly guarantee a causal relationship between these two dose parameters and SWAL M6 . Therefore, an essential step in assessing the generalizability and causality of the multivariable NTCP model for SWAL M6 was external validation in an independent patient cohort treated with a radiation technique in which the relevant dose parameters were further optimized [32] . The current study showed that the multivariable NTCP model for SWAL M6 still performed well in this independent patient cohort with a modified IMRT technique and that the predictions based on the actual treatment technique (SW-IMRT) corresponded very well with the observed prevalence."
In conclusion, we externally validated the multivariable NTCP model for SWAL M6 in a subsequent independent cohort of patients treated with SW-IMRT and showed that by reducing the dose parameters included in this NTCP model, the risk of swallowing dysfunction can be reduced.
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